Congestive Heart Failure Market Size, Share, Growth, Epidemiology and Forecast to 2036

(Albany, New York) – 17th Sep 2026 – DelveInsight’s latest report, “Congestive Heart Failure Market Insights, Epidemiology, and Market Forecast – 2036,” provides a comprehensive assessment of the Congestive Heart Failure market across the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan. The report evaluates historical and forecasted epidemiology, patient burden, treatment patterns, market dynamics, emerging therapies, competitive intelligence, drug uptake, reimbursement, pricing, and unmet needs through 2036.

According to DelveInsight, the 7MM Congestive Heart Failure market was valued at approximately USD 9,000 million in 2025 and is projected to reach approximately USD 19,000 million by 2036, representing an 8% CAGR during 2026–2036. The United States represented the largest market, with a Congestive Heart Failure treatment market size of approximately USD 6,500 million in 2025.

Key Takeaways from the Congestive Heart Failure Market

• The 7MM Congestive Heart Failure market was approximately USD 9,000 million in 2025.
• The market is projected to reach approximately USD 19,000 million by 2036, growing at an 8% CAGR during the forecast period.
• The United States accounted for the largest Congestive Heart Failure market, with a market size of approximately USD 6,500 million in 2025.
• In 2025, the US had approximately 4,597,000 patients with HFpEF, 2,128,000 with HFrEF, and 758,000 with HFmrEF.
• Japan recorded approximately 5,366,000 diagnosed prevalent heart failure cases in 2025, with the patient population expected to increase through 2036.
• Among the EU4, Germany had the highest number of diagnosed prevalent cases, followed by France and Spain, while Italy had the lowest in 2025.
• Key marketed therapies include INPEFA (sotagliflozin), INJECTAFER/FERINJECT (ferric carboxymaltose), JARDIANCE (empagliflozin), FUROSCIX (furosemide), and KERENDIA (finerenone).
• Emerging therapies include omecamtiv mecarbil, CardiAMP Cell Therapy, CRD-740, REVASCOR (rexlemestrocel-L), and others.
• Major companies involved in the Congestive Heart Failure market include Novartis, Boehringer Ingelheim, Eli Lilly and Company, Bayer, Cytokinetics, BioCardia, and Novo Nordisk.

Keen to know more about the Congestive Heart Failure market? Request a sample copy of the report for detailed market insights, epidemiology, treatment patterns, competitive intelligence, and forecast analysis. https://www.delveinsight.com/sample-request/congestive-heart-failure-market

Key Factors Driving the Congestive Heart Failure Market

Rising Prevalence of Congestive Heart Failure

The increasing incidence and prevalence of heart failure remain major contributors to market expansion. Aging populations and the growing burden of cardiovascular risk factors are expanding the patient pool requiring long-term management and pharmacological intervention. Heart failure is also a leading cause of hospitalization among individuals aged 65 years and above, creating a substantial clinical and economic burden.

Growing Geriatric Population

Older adults have a substantially higher risk of developing heart failure. The continued expansion of the geriatric population is therefore expected to increase the number of patients requiring diagnosis, treatment, monitoring, and supportive care.

Advancements in Diagnostic Technologies

Improvements in diagnostic approaches, including cardiac imaging and biomarkers such as BNP and NT-proBNP, are supporting earlier and more accurate identification of heart failure. Echocardiography also plays an important role in determining left ventricular ejection fraction and guiding treatment decisions.

Introduction of Novel Therapies

The treatment landscape has expanded with the introduction and broader use of therapies such as SGLT2 inhibitors, ARNIs, mineralocorticoid receptor antagonists, and other targeted treatments. Products such as INPEFA, JARDIANCE, FARXIGA, and KERENDIA are contributing to the evolving treatment paradigm across different heart failure phenotypes.

Strong Pipeline of Emerging Therapies

The Congestive Heart Failure pipeline includes several mid- to late-stage candidates using different mechanisms and therapeutic approaches. These include cardiac myosin activation, cell-based cardiac repair, HDAC inhibition, mineralocorticoid receptor antagonism, and other approaches designed to address persistent unmet needs.

Expansion of Combination and Personalized Treatment

The increasing use of multidrug treatment strategies and more individualized approaches is also supporting market development. Current heart failure management frequently combines multiple therapeutic classes to address different aspects of disease progression, congestion, cardiovascular risk, and cardiac function.

Competitive Landscape

The Congestive Heart Failure market comprises established pharmaceutical companies and emerging biotechnology companies developing innovative pharmacological and cell-based approaches.

Key companies include:

• Novartis
• Boehringer Ingelheim
• Eli Lilly and Company
• Bayer
• Cytokinetics
• BioCardia
• Novo Nordisk

The marketed treatment landscape includes INPEFA (sotagliflozin), INJECTAFER/FERINJECT, FUROSCIX, JARDIANCE, and other therapies, while emerging candidates such as omecamtiv mecarbil, CardiAMP Cell Therapy, and CRD-740 are being evaluated in clinical development.

Recent Developments in the Congestive Heart Failure Market

• November 2025: BioCardia announced enrollment of the first patient at Henry Ford Health in its ongoing Phase III CardiAMP HF II trial for patients with ischemic HFrEF.
• October 2025: BioCardia announced enrollment of the first patient at the University of Wisconsin School of Medicine and Public Health in the Phase III CardiAMP HF II trial.
• April 2025: An independent Data Safety Monitoring Board review of the 30-day safety data from the roll-in 20-million-cell dosing cohort of the CardiALLO-HF trial recommended continuation of the study as designed.
• July 2025: The US FDA approved KERENDIA (finerenone) for adults with heart failure and LVEF ≥40%, covering HFmrEF and HFpEF.
• June 2023: The US FDA approved INJECTAFER (ferric carboxymaltose) for treatment of iron deficiency in adults with NYHA Class II/III heart failure to improve exercise capacity.
• May 2023: The US FDA approved INPEFA (sotagliflozin) to reduce the risk of cardiovascular death, heart failure hospitalization, and urgent heart failure visits in specified adult patients.

What is Congestive Heart Failure?

Congestive Heart Failure is a progressive condition in which the heart is unable to pump sufficient blood to meet the body’s requirements without increased filling pressures. It may result from impaired ventricular systolic or diastolic function and is commonly classified according to left ventricular ejection fraction (LVEF).

Heart failure is broadly categorized into heart failure with reduced ejection fraction (HFrEF), heart failure with mildly reduced ejection fraction (HFmrEF), and heart failure with preserved ejection fraction (HFpEF). DelveInsight’s report identifies HFrEF as ≤40%, HFmrEF as 41–49%, and HFpEF as ≥50%.

Common symptoms include breathlessness, fatigue, and fluid retention, which can result in pulmonary congestion and peripheral edema. Diagnosis involves clinical evaluation, laboratory testing including BNP/NT-proBNP, ECG, chest X-ray, and echocardiography.

Current Treatment Landscape

Congestive Heart Failure management generally involves a multidrug therapeutic strategy. Commonly used treatment classes include ACE inhibitors, angiotensin II receptor blockers, beta-blockers, mineralocorticoid receptor antagonists, SGLT2 inhibitors, diuretics, If-channel inhibitors, digoxin, nitrates, and other supportive therapies.

Lifestyle modifications can include smoking cessation, limiting alcohol and caffeine, reducing dietary sodium and fluid intake where appropriate, and optimizing medical therapy. Patients with more advanced disease may require device-based interventions such as pacemakers or implantable cardioverter-defibrillators (ICDs).

Recent therapeutic advances include:

• INPEFA (sotagliflozin): Dual SGLT1/SGLT2 inhibitor approved for specified heart failure populations.
• JARDIANCE (empagliflozin): SGLT2 inhibitor used in heart failure management.
• INJECTAFER/FERINJECT: Intravenous iron replacement therapy for heart failure patients with iron deficiency.
• KERENDIA (finerenone): Mineralocorticoid receptor antagonist approved in 2025 for adults with heart failure and LVEF ≥40%.
• FUROSCIX: Subcutaneous furosemide delivery system for selected patients with congestion due to fluid overload.

Congestive Heart Failure Epidemiology

DelveInsight’s epidemiological analysis evaluates the heart failure burden across the 7MM using several segmentation categories, including total diagnosed prevalent cases, gender, ejection fraction, NYHA class, heart failure type, and age.

Key epidemiological findings include:

• In 2025, the US had approximately 4,597,000 HFpEF patients, 2,128,000 HFrEF patients, and 758,000 HFmrEF patients.
• In Japan, diagnosed prevalent heart failure cases reached approximately 5,366,000 in 2025.
• In Europe, females are more prevalent among heart failure patients, whereas the opposite trend is observed in the US.
• Among EU4 countries, Germany had the highest number of diagnosed prevalent cases in 2025, followed by France and Spain, while Italy had the lowest.
• Approximately 35–40% of acute heart failure patients do not have reduced LVEF, according to the report’s cited analysis.
• Patients with preserved LVEF tend to be older and more frequently female.

Unmet Needs in Congestive Heart Failure

Despite significant advances in treatment, important unmet needs remain across the heart failure patient journey:

1. Need for tailored and effective treatment options
2. Need for timely and accurate diagnosis
3. Need for prevention among individuals at risk
4. Limited treatment options for certain HFpEF and HFmrEF populations
5. Need for therapies capable of improving cardiac function and reducing hospitalization and mortality

The development of novel pharmacological and cell-based therapies is aimed at addressing some of these persistent gaps.

Scope of the Congestive Heart Failure Market Report

• Study Period: 2022–2036
• Historical Period: 2022–2025
• Forecast Period: 2026–2036
• Base Year: 2026
• Geographies: US, Germany, France, Italy, Spain, UK, and Japan
• 7MM Market Size, 2025: ~USD 9,000 million
• Projected Market Size, 2036: ~USD 19,000 million
• Market CAGR: 8%
• US Market Size, 2025: ~USD 6,500 million
• Epidemiology Segmentation: Total diagnosed prevalent cases, gender-specific cases, ejection fraction-specific cases, NYHA class-specific cases, type-specific cases, and age-specific cases
• Market Segmentation: Region/geographies and drugs/therapies
• Key Companies: Novartis, Boehringer Ingelheim, Eli Lilly and Company, Bayer, Cytokinetics, BioCardia, Novo Nordisk
• Key Therapies: INPEFA, INJECTAFER/FERINJECT, JARDIANCE, omecamtiv mecarbil, KERENDIA, VERQUVO, REVASCOR, TNX-103, and others
• Analysis: Addressable patient population, market drivers and barriers, cost assumptions and pricing analogues, KOL views, SWOT analysis, reimbursement, conjoint analysis, and unmet needs
• Key Strengths: Epidemiology-based bottom-up forecasting, AI-enabled market research, 11-year forecast, regional market outlook, patient burden assessment, treatment addressable market, competitive landscape, company insights, pricing and analogue assessment, therapy uptake, and peak patient share analysis.

To Know More About the Congestive Heart Failure Market Report

Congestive Heart Failure Market Insights, Epidemiology, and Market Forecast – 2036

Table of Contents

1. Report Introduction
2. Executive Summary
3. Key Events
4. Epidemiology and Market Methodology
5. Congestive Heart Failure Disease Overview
6. Causes, Risk Factors, Signs and Symptoms
7. Diagnosis and Diagnostic Algorithm
8. Congestive Heart Failure Treatment Landscape
9. Current Treatment Guidelines
10. Marketed Therapies
11. Emerging Therapies and Pipeline Analysis
12. Congestive Heart Failure Epidemiology
13. Patient Journey
14. Market Size and Forecast
15. Drug Uptake and Patient Share
16. Competitive Landscape
17. Market Drivers and Barriers
18. Unmet Medical Needs
19. Market Access and Reimbursement
20. Pricing and Analogue Assessment
21. KOL and SME Insights
22. SWOT and Conjoint Analysis
23. Regional Market Analysis
24. Company and Therapy Profiles
25. Market Outlook
26. Conclusions and Strategic Insights

About DelveInsight

DelveInsight is a leading market research and consulting firm specializing in the life sciences and healthcare industries. Founded in 2014, the company provides comprehensive market intelligence, epidemiology, and insights across pharmaceuticals, biotechnology, medical devices, and emerging therapies. DelveInsight helps healthcare organizations make informed strategic decisions through data-driven research and industry expertise.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kirti Sharma
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/